Biosynex SA (FR:ALBIO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biosynex SA, a leading health diagnostics group, has announced its 2025 financial calendar, starting with the release of its 2024 annual revenue on January 13. The company, known for its rapid tests and molecular biology solutions, continues to expand its presence in 95 countries with a strong focus on innovation in healthcare diagnostics.
For further insights into FR:ALBIO stock, check out TipRanks’ Stock Analysis page.